Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c
Kidney International · 2025
DOI: 10.1016/j.kint.2024.08.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2025. Verfasst von Max Brunkhorst und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Sodium-Phosphate Cotransporter Proteins, Type IIa, Sodium-Phosphate Cotransporter Proteins, Type IIc, Heterozygote, Parathyroid Hormone. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, European Society for Paediatric Oncology, European Rare Kidney Disease Reference Network.
Abstract (Originalsprache)
Pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter 2a and 2c are rare causes of phosphate wasting. Since data on presentation and outcomes are scarce, we collected clinical, biochemical and genetic data via an online questionnaire and the support of European professional organizations. One hundred thirteen patients (86% children) from 90 families and 17 countries with pathogenic or likely pathogenic variants in SLC34A1 or SLC34A3 and a median follow-up of three years were analyzed. Biallelic SLC34A1 variant carriers showed polyuria, failure to thrive, vomiting, constipation, hypercalcemia and nephrocalcinosis in infancy, while biallelic SLC34A3 carriers presented in childhood or even adulthood with rickets/osteomalacia and/or osteopenia/osteoporosis, hypophosphatemia and, less frequently, nephrocalcinosis, while the prevalences of kidney stones were comparable. Adult biallelic SLC34A3 carriers had a six-fold increase chronic kidney disease (CKD) prevalence compared to the general population. All biallelic variant carriers shared a common biochemical pattern including elevated 1,25(OH)2D and alkaline phosphatase levels, suppressed parathyroid hormone (PTH), and hypercalciuria. Heterozygous carriers showed similar but less pronounced phenotypes. In biallelic SLC34A1 carriers, an attenuation of clinical features was observed after infancy, independent of treatment. Phosphate treatment was given in 55% of patients, median duration two years, and resulted in significant reduction, although not normalization, of alkaline phosphatase and of hypercalciuria but an increase in PTH levels, while 1,25(OH)2D levels remained elevated. Thus, our study indicates that biallelic SLC34A1 and SLC34A3 carriers show distinct, albeit overlapping phenotypes, with the latter having an increased risk of CKD in adulthood. Phosphate treatment may promote kidney phosphate loss and enhance 1,25(OH)2D synthesis via increased PTH production.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School, Hannover, Germany.
- Department of Human Genetics, Division of Inherited & Acquired Kidney Diseases, Hannover Medical School, Hannover, Germany.
- Department of Hereditary and Acquired Kidney Diseases, Veltishev Research and Clinical Institute for Pediatrics and Children Surgery of Pirogov Russian National Research Medical University, Moscow, Russia.
- Department of Pediatric Nephrology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Pediatrics, Ruhr-University Bochum, Bochum, Germany.
- Department of Pediatric Endocrinology, Marmara University School of Medicine, Istanbul, Turkey.
Förderung
- Deutsche Forschungsgemeinschaft
- European Society for Paediatric Oncology
- European Rare Kidney Disease Reference Network
- Kyowa Kirin
Zitieren
APA
Brunkhorst, M., Brunkhorst, L., Martens, H., Papizh, S., Besouw, M., Grasemann, C., Turan, S., Sikora, P., Chromek, M., Cornelissen, E., Fila, M., Lilien, M., Allgrove, J., Neuhaus, T. J., Eltan, M., Espinosa, L., Schnabel, D., Gokce, I., González-Rodríguez, J. D., …, & Haffner, D. (2025). Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c. Kidney International. https://doi.org/10.1016/j.kint.2024.08.035
Vancouver
Brunkhorst M, Brunkhorst L, Martens H, Papizh S, Besouw M, Grasemann C, et al. Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c. Kidney International. 2025. doi:10.1016/j.kint.2024.08.035
BibTeX
@article{Brunkhorst2025,
author = {Brunkhorst, Max and Brunkhorst, Lena and Martens, Helge and Papizh, Svetlana and Besouw, Martine and Grasemann, Corinna and Turan, Serap and Sikora, Przemyslaw and Chromek, Milan and Cornelissen, Elisabeth and Fila, Marc and Lilien, Marc and Allgrove, Jeremy and Neuhaus, Thomas J and Eltan, Mehmet and Espinosa, Laura and Schnabel, Dirk and Gokce, Ibrahim and González-Rodríguez, Juan David and Khandelwal, Priyanka and Keijzer-Veen, Mandy G and Lechner, Felix and Szczepańska, Maria and Zaniew, Marcin and Bacchetta, Justine and Emma, Francesco and Haffner, Dieter},
title = {Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c},
journal = {Kidney International},
year = {2025},
doi = {10.1016/j.kint.2024.08.035}
}
EUVIMED